Biotech
Grail
Grail raises $390M Series D at $6.3B valuation
Menlo Park, CAMay 27, 20201 min read
Total Raised
$390M
Valuation
$6.3B
Latest Round
Series D
Employees
500+
Grail: Series D Funding Round
Grail has successfully raised $390M in Series D funding, reaching a valuation of $6.3B.
Company Overview
Multi-cancer early detection blood test
Funding Details
The Series D round was led by ARCH Venture Partners, with participation from Johnson & Johnson.
Company Information
- Headquarters: Menlo Park, CA
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Grail plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series D
- Johnson & Johnson: Verified investor in Series D
Company Info
Headquarters
Menlo Park, CA
Founded
2016
Team Size
500+
Last Round
$390M(May 2020)
Investors (2)
A
ARCH Venture PartnersLeadLead Investor
Verified investor in Series D
J
Johnson & JohnsonInvestor
Verified investor in Series D
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free